Clindamycin Pediatric Dose — Antimicrobial Reference
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, exhibiting bacteriostatic activity against a broad range of gram-positive organisms and anaerobes. It is widely used in pediatric practice for serious skin and soft-tissue infections, bone and joint infections, and infections caused by Staphylococcus aureus (including community-acquired MRSA in susceptible isolates) and anaerobic pathogens. Its excellent tissue and bone penetration make it a preferred agent in several pediatric infectious disease scenarios.
Pediatric Dosing
- Dose: 10 mg/kg/dose IV every 8 hours
- Adult/maximum dose: 600 mg IV every 8 hours — doses should not exceed the adult dose of 600 mg per administration
For a 20 kg child: 20 × 10 mg/kg = 200 mg IV every 8 hours. For a 40 kg adolescent: 40 × 10 mg/kg = 400 mg IV every 8 hours (below adult cap). For a child weighing 60 kg or more, the adult dose of 600 mg IV every 8 hours applies. Consult institutional protocol for neonatal dosing intervals, renal or hepatic dose adjustments, and oral step-down therapy.
Indications and Clinical Context
Clindamycin is indicated for moderate-to-severe infections where gram-positive cocci or anaerobic bacteria are suspected or confirmed, including complicated skin and soft-tissue infections (cSSTI), acute hematogenous osteomyelitis, septic arthritis, and pneumonia caused by susceptible organisms. It is a first-line or alternative agent for community-acquired MRSA infections per IDSA and institutional antimicrobial stewardship guidelines, contingent upon local susceptibility patterns. Its anti-toxin production effect at sub-inhibitory concentrations is particularly relevant in toxin-mediated conditions such as necrotizing fasciitis and streptococcal toxic shock syndrome.
In the context of PALS and pediatric critical care, clindamycin is frequently employed as part of combination empiric regimens for sepsis of skin, soft-tissue, or bone origin when coverage of MRSA or anaerobes is warranted. Susceptibility testing should guide definitive therapy wherever possible.
Administration and Monitoring
Clindamycin must be administered as a slow intravenous infusion; rapid IV push is not recommended due to the risk of cardiorespiratory adverse effects. Dilute appropriately per pharmacy guidance and infuse over a minimum of 10–60 minutes depending on the dose and institutional protocol. The IV and intramuscular (IM) routes are specified for inpatient use; oral step-down therapy should be guided by clinical response and bioavailability considerations.
- Monitor: Hepatic function with prolonged use; signs of Clostridioides difficile–associated diarrhea (clindamycin carries a notable risk)
- Key adverse effects: Diarrhea, pseudomembranous colitis, transaminase elevation, rash
- Contraindications: Known hypersensitivity to clindamycin or lincomycin; use with caution in patients with hepatic impairment or a history of antibiotic-associated colitis
- Max single dose: 600 mg IV per dose (adult dose ceiling)
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.